DK2056842T3 - Modificeret galactosylceramid til behandling af cancerøse sygdomme - Google Patents

Modificeret galactosylceramid til behandling af cancerøse sygdomme

Info

Publication number
DK2056842T3
DK2056842T3 DK07760333.0T DK07760333T DK2056842T3 DK 2056842 T3 DK2056842 T3 DK 2056842T3 DK 07760333 T DK07760333 T DK 07760333T DK 2056842 T3 DK2056842 T3 DK 2056842T3
Authority
DK
Denmark
Prior art keywords
galactosylceramide
modified
treatment
cancerous diseases
cancerous
Prior art date
Application number
DK07760333.0T
Other languages
English (en)
Inventor
Paul B Savage
Luc Teyton
Albert Bendelac
Original Assignee
Univ Chicago
Scrips Res Inst
Univ Brigham Young
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Chicago, Scrips Res Inst, Univ Brigham Young filed Critical Univ Chicago
Application granted granted Critical
Publication of DK2056842T3 publication Critical patent/DK2056842T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02Acyclic radicals, not substituted by cyclic structures
    • C07H15/04Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/06Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical being a hydroxyalkyl group esterified by a fatty acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK07760333.0T 2006-04-07 2007-04-09 Modificeret galactosylceramid til behandling af cancerøse sygdomme DK2056842T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79009606P 2006-04-07 2006-04-07
PCT/US2007/066250 WO2007118234A2 (en) 2006-04-07 2007-04-09 Modified -galactosyl ceramides for staining and stimulating natural killer t cells

Publications (1)

Publication Number Publication Date
DK2056842T3 true DK2056842T3 (da) 2013-01-14

Family

ID=38581864

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07760333.0T DK2056842T3 (da) 2006-04-07 2007-04-09 Modificeret galactosylceramid til behandling af cancerøse sygdomme

Country Status (12)

Country Link
US (2) US8227581B2 (da)
EP (1) EP2056842B1 (da)
AU (1) AU2007234753B2 (da)
BR (1) BRPI0710668A2 (da)
CA (1) CA2661789C (da)
DK (1) DK2056842T3 (da)
ES (1) ES2397975T3 (da)
PL (1) PL2056842T3 (da)
PT (1) PT2056842E (da)
SI (1) SI2056842T1 (da)
WO (1) WO2007118234A2 (da)
ZA (1) ZA200900905B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645873B2 (en) 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
CA2593715C (en) 2005-01-28 2015-05-05 Brigham Young University Bacterial glycolipid activation of cd1d-restricted nkt cells
AU2007269299B2 (en) 2006-06-30 2013-01-17 Brigham Young University Adjuvants and methods of use
US8916164B2 (en) * 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
EP2058011A1 (en) * 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
AU2013202865B2 (en) * 2007-11-07 2015-03-19 Abivax Increase of immune response and targeting by antigens and/or drug linkage
US8207135B2 (en) 2007-12-05 2012-06-26 Wittycell Compositions for and methods of enhancing the immune response to antigens
JP5809560B2 (ja) * 2008-10-08 2015-11-11 アビヴァックス インフルエンザに対して使用するためのワクチン組成物
ES2345377B1 (es) * 2009-03-20 2011-07-21 Consejo Superior De Investigaciones Cientificas (Csis) (51%) Compuestos aminociclitoles, procedimiento de obtencion y usos.
WO2011112889A2 (en) 2010-03-12 2011-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services β-MANNOSYLCERAMIDE AND STIMULATION OF NKT CELL ANTI-TUMOR IMMUNITY
ES2617510T3 (es) 2012-04-26 2017-06-19 Riken Nuevo carbamato de glicolípido y uso del mismo
WO2014001204A1 (en) 2012-06-28 2014-01-03 Universiteit Gent Galactopyranosyl derivatives useful as medicaments
EP2727929A1 (en) * 2012-10-30 2014-05-07 Wittycell Method of preparation of alpha galactosyl ceramides compounds
WO2014210522A1 (en) * 2013-06-28 2014-12-31 The Scripps Research Institute Nkt cell ligands and methods of use
US10046046B2 (en) * 2014-06-05 2018-08-14 Victoria Link Limited Amino sphingoglycolipid analogues
BR112019004906A2 (pt) 2016-09-14 2019-06-25 Abivax combinação incluindo abx196 para o tratamento de câncer
US12268700B2 (en) * 2018-03-26 2025-04-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 3-o-sulfo-galactosylceramide analogs as activators of type II NKT cells and uses thereof
WO2023121483A1 (en) * 2021-12-24 2023-06-29 Victoria Link Limited Immunostimulatory compositions
CN115286667B (zh) * 2022-08-02 2024-03-26 华中农业大学 一种α-半乳糖基神经酰胺类似物及其制备方法和应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242800A (en) * 1990-01-30 1993-09-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Receptor for pathogenic fungi
US5936076A (en) * 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
TW261533B (da) * 1992-07-16 1995-11-01 Kirin Brewery
EP0666268B1 (en) * 1992-10-22 2000-04-19 Kirin Beer Kabushiki Kaisha Novel sphingoglycolipid and use thereof
EP0694558B1 (en) * 1993-04-15 1999-01-27 Kirin Beer Kabushiki Kaisha Novel sphingoglycolipid and use thereof
RO117533B1 (ro) * 1993-05-14 2002-04-30 Cytel Corp San Diego DERIVATI DE ANALOGI SIALIL LeX INHIBITORI AI ADEZIUNII CELULARE SI COMPOZITIE FARMACEUTICA CU ACESTIA
US6054433A (en) * 1994-11-03 2000-04-25 The Regents Of The University Of California Methods and compositions for stimulating tissue growth and epithelial moisturization
US5785975A (en) * 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
EP0821068A3 (en) * 1996-03-29 1999-06-02 Rohm And Haas Company Novel sphingolipids and a process thereto
CN1121223C (zh) 1997-02-05 2003-09-17 麒麟麦酒株式会社 含有神经鞘糖脂的冷冻干燥组合物及其制造方法
US6417167B1 (en) * 1997-02-05 2002-07-09 Kirin Beer Kabushiki Kaisha Lyophilized compositions containing shingoglycolipid and process for preparing them
ATE286735T1 (de) 1997-04-10 2005-01-15 Kirin Brewery Verwendung von a-glycosylceramiden zur herstellung eines therapeutischen mittelszur behandlung von autoimmunkrankheiten
JP2001527046A (ja) 1997-12-30 2001-12-25 エイプラス サイエンス インベスト アーベー ガラクトシルセラミド、グルコシルセラミド、ラクトシルセラミド、並びに前糖尿病、糖尿病および/または関連合併症の予防もしくは治療に使用するためのその特定キャッチャー
EP1053243B1 (en) * 1998-02-12 2011-03-30 Emory University Sphingolipid derivatives and their methods of use
US20030157113A1 (en) * 1999-12-28 2003-08-21 Terman David S. Compositions and methods for treatment of neoplastic disease
AU2001252599A1 (en) * 2000-04-28 2001-11-12 Orient Cancer Therapy Co., Ltd. Remedies for cancer
JP4410913B2 (ja) * 2000-06-12 2010-02-10 壽製薬株式会社 新規糖脂質誘導体の製造方法
WO2001098317A2 (en) * 2000-06-22 2001-12-27 The Brigham And Women's Hospital, Inc. Alpha-glycosylceramides for treating bacterial and fungal infections
WO2002018539A2 (en) * 2000-08-25 2002-03-07 Lysometrix Corporation Method for assaying the activity of lysosomal enzymes
CN1561389A (zh) * 2001-07-25 2005-01-05 纽约大学 糖基神经酰胺作为用于抗传染病和癌症的疫苗的佐剂的用途
KR100549866B1 (ko) 2001-08-22 2006-02-08 고려대학교 산학협력단 암치료 및 예방 제제
CN1578667A (zh) * 2001-11-06 2005-02-09 东方癌症治疗株式会社 抗癌组合物
US7273853B2 (en) * 2002-05-13 2007-09-25 Enanta Pharmaceuticals, Inc. 6-11 bicyclic ketolide derivatives
WO2003105769A2 (en) 2002-06-13 2003-12-24 New York University Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
US7645873B2 (en) * 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
WO2004094444A1 (en) * 2003-03-20 2004-11-04 Brigham Young University 6'-amino-6'-deoxygalactosylceramides
GB0314682D0 (en) 2003-06-24 2003-07-30 Isis Innovation Materials and methods relating to the modulation of T cell response to soluble antigen
US7771726B2 (en) * 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
CN1964626A (zh) 2004-03-31 2007-05-16 纽约大学 新型合成c-糖脂、其合成及其治疗传染病、癌症和自身免疫性疾病的用途
CA2577009C (en) 2004-08-27 2017-05-02 Albert Einstein College Of Medicine, Inc. Ceramide derivatives as modulators of immunity and autoimmunity
JP5005541B2 (ja) * 2004-09-03 2012-08-22 ザ ユニヴァーシティー オヴ シカゴ Nkt細胞の活性化方法
JP5090928B2 (ja) * 2004-12-28 2012-12-05 ザ ロックフェラー ユニバーシティ Nkt細胞に対する抗原としての糖脂質及びその類似体
CA2593715C (en) 2005-01-28 2015-05-05 Brigham Young University Bacterial glycolipid activation of cd1d-restricted nkt cells
KR100764678B1 (ko) 2005-07-13 2007-10-09 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드를 아쥬반트로 포함하는 비강투여용 백신 조성물
EP1945651B1 (en) 2005-10-25 2014-06-25 The Ludwig Institute for Cancer Research Analogs of alpha galactosylceramide and uses thereof
AU2007269299B2 (en) * 2006-06-30 2013-01-17 Brigham Young University Adjuvants and methods of use
EP1938836A1 (en) 2006-12-28 2008-07-02 Universite Rene Descartes (Paris V) Compositions comprising a B subunit of shiga toxin and a means stimulating NKT cells

Also Published As

Publication number Publication date
AU2007234753A1 (en) 2007-10-18
US20090047299A1 (en) 2009-02-19
EP2056842A2 (en) 2009-05-13
CA2661789C (en) 2014-06-03
EP2056842B1 (en) 2012-10-17
AU2007234753B2 (en) 2013-02-21
PT2056842E (pt) 2013-01-24
ES2397975T3 (es) 2013-03-12
WO2007118234A2 (en) 2007-10-18
SI2056842T1 (sl) 2013-02-28
US20120270815A1 (en) 2012-10-25
CA2661789A1 (en) 2007-10-18
EP2056842A4 (en) 2010-10-06
WO2007118234A3 (en) 2007-12-06
US8227581B2 (en) 2012-07-24
ZA200900905B (en) 2010-06-30
US8765692B2 (en) 2014-07-01
PL2056842T3 (pl) 2013-03-29
BRPI0710668A2 (pt) 2011-08-16

Similar Documents

Publication Publication Date Title
DK2056842T3 (da) Modificeret galactosylceramid til behandling af cancerøse sygdomme
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
HUE054495T2 (hu) Rák kezelésére szolgáló készítmény
DK1874781T3 (da) Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
SMAP200900085A (it) 3-imidazolil-indoli per il trattamento di malattieproliferative
DK3457135T3 (da) Behandlingsmuligheder til fabrys sygdom
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
BRPI0821779A2 (pt) tratamento terapêutico de câncer
DK2154971T3 (da) Synergistisk farmaceutisk kombination til behandling af cancer
DK3289876T3 (da) Forbindelser til behandling af cancer
DK2047863T3 (da) Middel til forebyggelse eller behandling af inflammatoriske sygdomme
DK2121139T3 (da) Formulations for cancer treatment
DK2285808T3 (da) Spiroindolderivater til behandling af parasitsygdomme
ZA201001304B (en) Compositions for the treatment of neoplastic diseases
DK2056807T3 (da) Behandling af inflammatoriske sygdomme
PL2338519T3 (pl) Środek do leczenia zwłóknienia szpiku
DK2035369T3 (da) Terapeutiske
BRPI0815551A2 (pt) Tratamento através de hucbc de doença beta-amiloide
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
PL2205720T3 (pl) Kompozycja do leczenia stwardnienia rozsianego
DK2022504T3 (da) Salve til behandling af hæmorider
DK2099446T3 (da) Fremgangsmåde til behandling af inflammatorisk tarmsygdom